Key facts
- Juvena Therapeutics’s last known valuation is $100.0M (Nov 2022).
- It has raised $132.2M across 2 recorded rounds; the latest was Early Stage VC ($30.5M) in Jun 2025.
- Notable investors include Alumni Ventures, Creative Destruction Lab, Liquid 2 Ventures, Global Founders Capital, StartX (US) — 34 tracked in total.
- Juvena Therapeutics has filed 2 Form Ds with the SEC since 2018, most recently Jul 2025 ($30.5M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for Juvena Therapeutics
Funding rounds
2 roundsAbout Juvena Therapeutics
Developer of a biopharmaceutical drug discovery platform intended to discover novel protein-based therapeutics. The company's platform screens restored cellular functions to produce rejuvenating protein-based therapeutics that promote tissue regeneration and repair to treat chronic and rare diseases, enabling healthcare professionals to decode secreted proteins for chronic and age-related diseases.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2017
- Employees
- 44
- Website
- juvenatherapeutics.com/
- Ownership
- Privately Held (backing)
Juvena Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juvena Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juvena Therapeutics in its N-PORT filings yet. We sweep new filings monthly.